keyword
https://read.qxmd.com/read/38536173/patient-reported-adverse-events-and-early-treatment-discontinuation-among-patients-with-multiple-myeloma
#1
JOURNAL ARTICLE
John Devin Peipert, Fengmin Zhao, Ju-Whei Lee, Shu-En Shen, Edward Ip, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Pamela J Raper, Matthias Weiss, Shaji K Kumar, S Vincent Rajkumar, David Cella, Robert Gray, Lynne I Wagner
IMPORTANCE: There is substantial interest in capturing cancer treatment tolerability from the patient's perspective using patient-reported outcomes (PROs). OBJECTIVE: To examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events. DESIGN, SETTING, AND PARTICIPANTS: This prospective survey study was conducted from February to April 2023...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38534879/prevalence-outcomes-and-impact-of-disease-related-complications-in-the-survival-of-multiple-myeloma-patients
#2
JOURNAL ARTICLE
Wachiralak Tothong, Adisak Tantiworawit, Lalita Norasetthada, Chatree Chai-Adisaksopha, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Ekarat Rattarittamrong
There are limited data regarding the impact of disease-related complications on the survival of multiple myeloma (MM) patients. The primary objective of this study was to determine the prevalence of disease-related complications, including hypercalcemia, renal insufficiency, anemia, and bone lytic lesions in MM patients. The secondary objectives were to determine clinical characteristics, treatment outcomes, and the association of disease-related complications and mortality. A retrospective chart review of MM patients from November 2014 to December 2019 was conducted...
February 21, 2024: Hematology Reports
https://read.qxmd.com/read/38534209/performance-characteristics-and-limitations-of-the-available-assays-for-the-detection-and-quantitation-of-monoclonal-free-light-chains-and-new-emerging-methodologies
#3
REVIEW
Hannah V Giles, Kamaraj Karunanithi
Light chain measurements form an essential component of the testing strategy for the detection and monitoring of patients with suspected and/or proven plasma cell disorders. Urine-based electrophoretic assays remain at the centre of the international guidelines for response assessment but the supplementary role of serum-free light chain (FLC) assays in response assessment and the detection of disease progression due to their increased sensitivity has been increasingly recognised since their introduction in 2001...
March 11, 2024: Antibodies
https://read.qxmd.com/read/38534054/successful-treatment-of-refractory-orbital-plasmacytoma-with-chimeric-antigen-receptor-t-cell-therapy-a-case-report-and-review-of-the-literature
#4
JOURNAL ARTICLE
Rebecca Z Lin, Tracy Lu, Natalie Homer, Clara J Men
Orbital plasmacytoma is a rare plasma cell tumor that may arise as an aggressive form of extramedullary multiple myeloma. Treatment modalities include surgical excision, radiation, and chemotherapy. Chimeric antigen receptor T cell therapy is currently reserved for refractory disease. The authors present a case of a 69-year-old woman with an extensive orbital plasmacytoma refractory to multimodal therapy who was treated with idecabtagene vicleucel chimeric antigen receptor T cell therapy. Four days after infusion, the patient exhibited grade 1 cytokine release syndrome, which resolved with tocilizumab...
March 21, 2024: Ophthalmic Plastic and Reconstructive Surgery
https://read.qxmd.com/read/38531841/outcomes-of-patients-with-multiple-myeloma-refractory-to-standard-dose-vs-low-dose-lenalidomide
#5
JOURNAL ARTICLE
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment...
March 26, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38529782/regression-of-intermediate-high-risk-monoclonal-gammopathy-of-undetermined-significance-mgus-with-long-term-use-of-curcumin-a-case-report
#6
JOURNAL ARTICLE
Terry Golombick, Rajeev Ramakrishna, Arumugam Manoharan
Patients with intermediate-high risk MGUS are not offered therapeutic options to date and standard of care remains observation with re-evaluations of the patient every 3 to 6 months. Given the persistent risk of progression as well as potential complications experienced by some, and anxiety experienced by most patients, early intervention with non-toxic curcumin, aimed at potentially slowing down or stopping disease progression might be therapeutic. We present here an intermediate-high risk MGUS patient who has been taking curcumin for 16 years and has shown a decrease in disease markers and an increase in uninvolved immunoglobulins, adding to the body of evidence of benefit of curcumin to MGUS patients...
2024: Integrative Cancer Therapies
https://read.qxmd.com/read/38529443/multiple-myeloma-a-rare-presentation-as-unilateral-pleural-effusion
#7
Kalyani Deshmukh, Kajal Hatgoankar, Milind Pande, Parag Sabale, Nandkishor J Bankar
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. It commonly presents with bone pain, anemia, renal failure, and hypercalcemia. Pleural effusion in MM usually has multiple causes, but it is rare for the effusion to be due to myelomatous deposition of the pleura. Here, we present a rare case in which the patient presented to the outpatient department with a dry cough, breathlessness, and generalized weakness. The patient was diagnosed with MM with myelomatous pleural effusion (MPE), highlighting the importance of considering MM as a differential diagnosis in patients with atypical presentations...
February 2024: Curēus
https://read.qxmd.com/read/38529413/synergistic-integration-of-histone-deacetylase-inhibitors-apparently-enhances-the-cytokine-induced-killer-cell-efficiency-in-multiple-myeloma-via-the-nkg2d-pathway
#8
JOURNAL ARTICLE
Jingjing Pu, Amit Sharma, Ting Liu, Jian Hou, Ingo Gh Schmidt-Wolf
OBJECTIVES: The rapid recognition of epigenetic manipulation's potential in restricting cancer cell capabilities spurred translational initiatives, including histone deacetylase inhibitors (HDACis). Clinical trials on multiple myeloma (MM) demonstrated substantial benefits of HDACis, coupled with promising outcomes from cytokine-induced killer cell (CIK) immunotherapy. Intriguingly, the unexplored synergy of HDACis and CIK cell immunotherapy in MM prompted our study. METHODS: We examined clinically relevant HDACis (panobinostat/LBH589 and romidepsin) alongside CIK cells derived from peripheral blood mononuclear cells across diverse MM cell lines (U266, RPMI8226, OPM-2 and NCI-H929)...
2024: Clinical & Translational Immunology
https://read.qxmd.com/read/38529002/superior-oblique-muscle-extramedullary-plasmacytoma-in-a-patient-with-multiple-myeloma-and-a-review-of-literature
#9
Amirreza Veisi, Kimia Daneshvar, Sadid Hooshmandi, Maryam Najafi, Peyman Mohammadi Torbati, Kiana Hassanpour
INTRODUCTION: Multiple myeloma (MM), a plasma cell malignancy, is a systemic disease affecting various body organs. Plasmacytoma of bone and extramedullary disease (EMD) are presentations of MM. EMD is usually the sign of a more aggressive form of the disease. Herein, we report a patient with refractory MM presenting with extramedullary plasmacytoma in the superior oblique (SO) muscle. CASE PRESENTATION: A 51-year-old female presented complaining of gradual protrusion of the left eye and ocular pain from 20 days prior...
2024: Case Reports in Ophthalmology
https://read.qxmd.com/read/38528948/utilizing-medical-thoracoscopy-for-the-diagnosis-of-myelomatous-pleural-effusion-2-case-reports
#10
Khai Lip Ng, Sin Nee Tan, Nai-Chien Huan, Mona Zaria Nasaruddin, Noriah Othman, Jamalul Azizi Abdul Rahaman
Multiple myeloma (MM) is characterized by neoplastic proliferation of monoclonal antibody producing plasma cells. In clinical practice, pleural effusion is seen in up to 6% of MM patients, with many causative factors. Nevertheless, true myelomatous pleural effusion, defined as infiltration of the pleura by myeloma cells, is very rare. In this case report, we present two patients with biopsy proven myelomatous pleural effusion. The first patient developed myelomatous pleural effusion as initial presentation while the second patient's pleural effusion occurred during disease relapse...
March 2024: Respirology Case Reports
https://read.qxmd.com/read/38528354/are-the-glim-criteria-guiding-in-the-course-of-hematological-malignancies
#11
JOURNAL ARTICLE
F Yilmaz, M R Aras, Hba Ozturk, H N Sahin, A K Gunes, M Albayrak
BACKGROUND: Different degrees of malnutrition are seen in patients with hematological malignancies. None of the approaches used to determine malnutrition risk have general acceptance. The use of the GLIM criteria developed by the Global Leadership Initiative on Malnutrition has promising results. MATERIALS AND METHODS: A total of 67 patients with leukemia, lymphoma, and multiple myeloma were included in the study. NRS-2002 (Nutritional Risk Screening-2002) was used to screen the nutritional status of the patients, and malnutrition was diagnosed and graded using the GLIM criteria in patients who were found to be at risk of malnutrition in this test...
March 1, 2024: Nigerian Journal of Clinical Practice
https://read.qxmd.com/read/38528120/targeting-the-chromatin-binding-of-exportin-1-disrupts-nfat-and-t-cell-activation
#12
JOURNAL ARTICLE
Yi Fan Chen, Maryam Ghazala, Ryan M Friedrich, Brittany A Cordova, Frederick N Petroze, Ramya Srinivasan, Kevin C Allan, David F Yan, Joel L Sax, Kelley Carr, Suzanne L Tomchuck, Yuriy Fedorov, Alex Y Huang, Amar B Desai, Drew J Adams
Exportin-1 (XPO1/CRM1) plays a central role in the nuclear-to-cytoplasmic transport of hundreds of proteins and contributes to other cellular processes, such as centrosome duplication. Small molecules targeting XPO1 induce cytotoxicity, and selinexor was approved by the Food and Drug Administration in 2019 as a cancer chemotherapy for relapsed multiple myeloma. Here, we describe a cell-type-dependent chromatin-binding function for XPO1 that is essential for the chromatin occupancy of NFAT transcription factors and thus the appropriate activation of T cells...
March 25, 2024: Nature Chemical Biology
https://read.qxmd.com/read/38527835/-clinical-analysis-of-14-patients-aged-%C3%A2-50-years-with-high-risk-multiple-myeloma-treated-with-allogeneic-hematopoietic-stem-cell-transplantation
#13
JOURNAL ARTICLE
P Pan, J L Wang, W H Zhai, Q L Ma, D L Yang, S Z Feng, M Z Han, A M Pang, E L Jiang
Objective: To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in young patients with high-risk multiple myeloma (HRMM) and analyzed the factors affecting patient prognosis. Methods: In this retrospective study, we analyzed the clinical data of 14 patients with HRMM with cytogenetic abnormalities or high-risk biological factors who underwent allo-HSCT at the Hematopoietic Stem Cell Transplantation Center of the Institute of Hematology & Blood Diseases Hospital between November 2016 and November 2022...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527834/-clinical-features-and-risk-factors-for-invasive-fungal-sinusitis-after-allogeneic-hematopoietic-stem-cell-transplantation
#14
JOURNAL ARTICLE
H X Fu, J J Li, Y Y Zhang, Y Q Sun, X D Mo, T T Han, J Kong, M Lyu, W Han, H Chen, Y Y Chen, F R Wang, C H Yan, Y Chen, J Z Wang, Y Wang, L P Xu, X J Huang, X H Zhang
Objective: To analyze the clinical characteristics and outcomes of patients with invasive fungal sinusitis (invasive fungal rhinosinusitis, IFR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and explored the risk factors for IFR after allo-HSCT. Methods: Nineteen patients with IFR after allo-HSCT at Peking University People's Hospital from January 2012 to December 2021 were selected as the study group, and 95 patients without IFR after allo-HSCT during this period were randomly selected as the control group (1:5 ratio) ...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38527433/utility-of-echocardiogram-in-neutropenic-patients-with-gram-positive-bacteremia-a-retrospective-study
#15
Neta Sternbach, Haim Ben-Zvi, Ofir Wolach, Moshe Yeshurun, Pia Raanani, Dafna Yahav, Liat Shargian
INTRODUCTION: Hemato-oncology patients are vulnerable to bloodstream infections due to immunocompromised state and use of intravascular catheters. Data regarding risk of infective endocarditis (IE) among those with gram positive bacteremia is limited. We aimed to evaluate the incidence of IE among neutropenic hemato-oncology patients, and to explore the yield of echocardiogram in this population. METHODS: we conducted a single retrospective study of all hospitalized hemato-oncology neutropenic patients with gram positive blood cultures between 2007 and 2021...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38527425/the-ratio-of-serum-urea-nitrogen-to-albumin-is-a-better-predictor-of-os-in-mm-patients-than-urea-nitrogen-alone
#16
JOURNAL ARTICLE
Jiaqi Shao, Enfan Zhang, Haoguang Chen, Zhen Cai, Mengmeng Dong
Introduction Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Abnormally cloned plasma cells secrete large amounts of monoclonal immunoglobulins in the bone marrow of MM patients. Serum urea nitrogen (sUN) is a byproduct of protein metabolism, and its effect on MM patients' prognoses remains unknown. Therefore, we analysed MM patients' clinical data to explore the role of sUN and serum urea nitrogen/serum albumin (sUAR) in the baseline tumor load and MM prognosis of MM patients. Methods We downloaded the clinical data of 762 MM patients from the MMRF database...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38524572/unusual-body-weight-loss-due-to-primary-hyperparathyroidism-a-case-study-with-literature-review
#17
Yan-Yu Lin, Shuen-Fu Weng, Ting-Teng Yang, Yi-Wei Lee, Ju-Han Liu, Yu-Shan Hsieh
Brown tumors (osteitis fibrosa cystica) are rare pathognomonic signs that occur in patients with primary hyperparathyroidism (PHPT). Brown tumors can exist in multiple bones and can easily be misdiagnosed as a metastatic tumor or multiple myeloma. It is also localized in the forearm, humerus, and leg. The symptoms of hypercalcemia, pathologic fracture, and bodyweight loss may increase the diagnostic difficulty of brown tumors because multiple myeloma and bone metastasis also show the same symptoms. We studied a 68-year-old woman who had experienced unusual bodyweight loss in the past 6 months (56kg-40kg) and bone pain...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524535/exploring-cellular-immunotherapy-platforms-in-multiple-myeloma
#18
REVIEW
Manh-Cuong Vo, Sung-Hoon Jung, Van-Tan Nguyen, Van-Dinh-Huan Tran, Nodirjon Ruzimurodov, Sang Ki Kim, Xuan-Hung Nguyen, Mihee Kim, Ga-Young Song, Seo-Yeon Ahn, Jae-Sook Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim, Je-Jung Lee
Despite major advances in therapeutic platforms, most patients with multiple myeloma (MM) eventually relapse and succumb to the disease. Among the novel therapeutic options developed over the past decade, genetically engineered T cells have a great deal of potential. Cellular immunotherapies, including chimeric antigen receptor (CAR) T cells, are rapidly becoming an effective therapeutic modality for MM. Marrow-infiltrating lymphocytes (MILs) derived from the bone marrow of patients with MM are a novel source of T cells for adoptive T-cell therapy, which robustly and specifically target myeloma cells...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38524403/challenges-and-outcomes-of-the-first-stem-cell-transplant-program-in-tanzania-east-africa
#19
JOURNAL ARTICLE
Stella Rwezaula, Mbonea Yonazi, Amey Panchal, Ashish Dhoot, Jemy Mathew, Sonu Tony, Sandeep Rao, Peter Muhoka, Samira Mahfudh, Neema Budodi, Mabula Kasubi, Flora Ndobho, Helena Kakumbula, Koga Luhulla, Linda Kapesa, Heri Tungaraza, Sarah Nyagabona, Agnes Shayo, Felister Seleki, Janeth Mtenga, Khadija Mwamtemi, Musa Suko, Isaac Mbughi, Mariana Shirima, Alfayo Mkisi, Rahma Ally, Malselina Kyaruzi, Else Arola Myaka, Johari Matiku, Mariam Nyamwaira, Saranya Nair, Aswathy Asokan, Goutham Kumar, Raj Badavath, Hedwiga Swai, Lawrence Museru, B S Ajaikumar, Deogratius Beda, Sachin Jadhav
INTRODUCTION: Due to the significant resources involved in creating HSCT programs there is a significant disparity in the availability of this treatment modality between the developed and developing countries. This manuscript details the process and the outcomes of the first HSCT program in East Africa which was started at Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania. MATERIALS AND METHODS: Information and data were collected on the processes which had been implemented for starting the HSCT program at MNH...
2024: Advances in Hematology
https://read.qxmd.com/read/38523673/the-role-of-proteasomes-in-tumorigenesis
#20
REVIEW
Xiangyi Zhou, Ruqing Xu, Yue Wu, Li Zhou, Tingxiu Xiang
Protein homeostasis is the basis of normal life activities, and the proteasome family plays an extremely important function in this process. The proteasome 20S is a concentric circle structure with two α rings and two β rings overlapped. The proteasome 20S can perform both ATP-dependent and non-ATP-dependent ubiquitination proteasome degradation by binding to various subunits (such as 19S, 11S, and 200 PA), which is performed by its active subunit β1, β2, and β5. The proteasome can degrade misfolded, excess proteins to maintain homeostasis...
July 2024: Genes & Diseases
keyword
keyword
1187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.